Cardior Pharmaceuticals

📍 Hanover, Germany🗓 Founded 2016👥 17 employees💰 Last funded Jul 2022
Pharmaceutical Manufacturing🌐 cardior.de
Website LinkedIn
Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide. As of May 2, 2024 Cardior Pharmaceuticals GmbH is a wholly owned subsidiary of Novo Nordisk Region Europe A/S.
6
Total investors
3
Early stage
2
Mid stage
1
Late stage
2016
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Germany
6
Investor activity2017–2022 · investors recorded per year
2017220181201912021120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Cardior Pharmaceuticals?
Cardior Pharmaceuticals has 6 investors on record on gritt.io, including 3 early-stage backers, 2 mid-stage and 1 late-stage investors.
When did Cardior Pharmaceuticals last raise funding?
The most recent investment in Cardior Pharmaceuticals recorded on gritt.io was in July 2022.
When was Cardior Pharmaceuticals founded?
Cardior Pharmaceuticals was founded in 2016.
What industry is Cardior Pharmaceuticals in?
Cardior Pharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Cardior Pharmaceuticals based?
Cardior Pharmaceuticals is headquartered in Hanover, Germany.